JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation
Clinical trial NCT05194995 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05194995
- Sponsor
- Allist Pharmaceuticals, Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-02-17
- Primary completion
- 2025-04-30
- Enrollment
- 48
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.